Print page Share page

Our pipeline centers on promising internally developed compounds.

 

Each was discovered by our own people. Each targets proven pathways to disrupting cancer growth. Each has potential for important patient impact.

Our Pipeline

PRECLINICAL PHASE 1 PHASE 2 PHASE 3 APPROVED (U.S., EU and Australia)
Iclusig® (ponatinib)*
CML, Ph+ ALL (refractory)
CML, Ph+ ALL (Japanese patients)
Gastrointestinal stromal tumors (KIT)
Lung cancer (FGFR)
Lung cancer (RET)
AML (FLT3)
Ph+ ALL (with chemo, 1st, 2nd line)
Medullary thyroid cancer (RET)
Biliary cancer (FGFR)
Brigatinib (AP26113)
Non-small cell lung cancer (ALK)
AP32788
Non-small cell lung cancer

* Includes investigator-sponsored trials.
  In some trials, enrollment of new patients is on hold.

Iclusig: Click here for full U.S. prescribing information and Medication Guide (PDF), including Boxed Warning.

You are now leaving this website. If you would like to continue, click Continue.
CancelContinue